SCHEMBL13049711

SCHEMBL13049711

CSc1ccc(-c2oc3ccccc3c2CO)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.49
▸ ALDH1A1 P00352 5/20 0.49
▸ HPGD P15428 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ GAA P10253 2/20 0.49
▸ GLA P06280 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ VKORC1 Q9BQB6 1/20 0.47
▸ LMNA P02545 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ RET P07949 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP3A4 P08684 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049701 0.83 LMNA (0.57) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL2962849 0.82 KMT2A (0.53) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049706 0.81 PTPN1 (0.45) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13080176 0.80 CYP3A4 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049703 0.77 PTGS2 (0.59) ALDH1A1HPGDSMN1; SMN2LMNATP53
SCHEMBL13049776 0.77 LMNA (0.39) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049721 0.77 MAPK14 (0.49) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049764 0.77 PTPN1 (0.43) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049759 0.77 CYP19A1 (0.52) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL13049712 0.76 PTGS2 (0.45) KDM4EALDH1A1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 KDM4E 4759/4885ALDH1A1 2902/4885HPGD 3422/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 KDM4E 4807/4885ALDH1A1 3108/4885HPGD 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback